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Among 155 clinical respiratory isolates of Haemophilus influenzae in Korea, 6 
(3.9%) isolates had reduced levofloxacin susceptibility (MICs ≥ 0.5 μg/mL). 
These six isolates had no significant quinolone resistance-determining region 
(QRDR) mutations in gyrA, gyrB, parC, or parE. This phenomenon suggests that 
neither evolution nor spread of any significant QRDRs mutations in clinical iso-
lates occurred in Korea. Therefore, continued surveillance is necessary to observe 
the evolution of antibiotic-resistance and take measures to avoid the spread of 
drug-resistant clones. 
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Phenotypic resistance to fluoroquinolones is rarely seen in Haemophilus influenzae, 
but recent studies suggest that reduced susceptibility due to mutational hot spots in 
the quinolone resistance-determining regions (QRDRs) of genes encoding gyrase 
(gyrA and gyrB) and DNA topoisomerase IV (parC and parE) may be common.1-4 
The mutational hot spots in gyrA (Ser84Thr), parC (Ser84Ile), gyrA (Asp88Asn), 
and parC (Glu88Lys) with reduced susceptibility generally remain undetected 
when fluoroquinolone susceptibility tests are interpreted using current break-
points.3,5 However, it is important to detect these mutations because they may be as-
sociated with clinical failures, and high-level resistance may emerge during fluoro-
quinolone therapy.4,5 Tentatively proposed breakpoints for levofloxacin, cipro-
floxacin, moxifloxacin (MICs ≥ 0.5 μg/mL), and nalidixic acid (MICs ≥ 32 μg/mL) 
could be used to detect decreased fluoroquinolone susceptibility in H. influenzae 
strains. 
We sought to define the relationship between amino acid changes in the QRDRs 
of gyrA, gyrB, parC, and parE, and decreased susceptibility to levofloxacin (MICs 
≥ 0.5 μg/mL) among respiratory infection-inducing 155 H. influenzae isolates Quinolone Resistance of H. Influenzae from Korea
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from a tertiary hospital in Korea. We retrospectively tested 
all H. influenzae cultured from clinical respiratory isolates 
obtained between 2001 and 2005. The MICs of levofloxa-
cin were measured using the Etest method.6,7 Previously de-
scribed or modified primers were used to define mutations 
in the gyrA, gyrB, parC, and parE genes.3 PCR primer se-
quences were determined from Genebank entry Rd KW20 
at the following positions gyrA (96 to 114; 549 to 567), 
gyrB (1194 to 1213; 1875 to 1894), parC (120 to 141; 699 
to 720), and parE (945 to 966; 1637 to 1656). These primer 
sequences included the known mutational hot spots in QR-
DRs (for example, Ser84Thr and Asp88Asn in gyrA, Ser-
467Thr and Asn601Ser in gyrB, Ser84Ile and Glu88Lys in 
parC, and Asp420Asn, Ser458Ala, and Ser474Asn in 
parE). Direct sequencing of the PCR products was carried 
out using an ABI Prism 3100 genetic analyzer (Applied 
Biosystems, Foster City, CA, USA). All sequences were 
compared to those of H. influenzae RD KW20 and non-
typeable H. influenzae 86-028NP. These two strains have 
traditionally been considered as the reference sequences of 
H. influenzae. In addition, these two strains are susceptible 
to fluoroquinolone. β-lactamase production was determined 
using the nitrocefin test (Oxoid, Basingstoke, UK). Sero-
type b primers were used to amplify the portion of the gene 
encoding the serotype b capsule.8 We used quality control 
strains H. influenzae ATCC 49247 and ATCC 49766 as 
controls for Etest and direct sequencing.
Six of the 155 clinical respiratory isolates (3.9%) had de-
creased susceptibility to levofloxacin (MICs ≥ 0.5 μg/mL). 
Of the 6 isolates with reduced susceptibility, 1 was serotype 
b and and 2 were β-lactamase producers. The QRDRs of 
gyrA, gyrB, parC, and parE were sequenced in the six iso-
lates, and no significant substitutions in gyrA, gyrB, and 
parE were found (Table 1). Although new substitutions of 
Ala120Ser, Lyn131glu, and Val210Leu in parC were re-
vealed in this study, the biological relevance of these parC 
substitutions is unknown. The association between the 
Asn138Ser substitution in parC and fluoroquinolone resis-
tance had been previously reported;3 however, this substitu-
tion has been found in susceptible H. influenzae 2 Further-
more, Ser133Thr and Gly206Arg substitutions in parC 
have been found in susceptible H. influenzae strains. These 
substituted sequences at codon 133, 138, and 206 of parC 
are identical to those in the non-typeable H. influenzae 
strain 86-028NP. The new substitutions in parC Ala120Ser, 
Lyn131glu, and Val210Leu were not noted in ATCC 49247 
or in ATCC 49766 H. influenzae. The clinical significance 
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